Durham-based 410 Medical which in May a new and improved version of LifeFlow, its medical device for treating life-threatening low blood pressure, shock and sepsis in critically ill patients, has raised $8 million in venture capital.
Read More
Here is a rewind of the past week’s headlines as reported by WRAL TechWire – 77 stories across the breadth of tech and life science.
Read More
Hatteras Venture Partners sees continued growth in the biotech and healthcare sectors as it begins investing from its sixth fund, says General Partner Clay Thorp in an exclusive interview.
Read More
Hatteras Venture Partners, one of the largest and most active venture capital funds based in North Carolina, has closed on the first $94 million of a new fund.
Read More
The four-year-old startup that focuses on the use of ribonucleic acid, a nucleic acid present in all cells known as RNA, to target disease, recently closed on a $30 million Series A round.
Read More
Precision cancer drug startup GeneCentric Therapeutics has a new CEO with its founder taking on the role as executive chairperson of the venture capital-backed startup’s board.
Read More
StrideBio, a life science startup focused on gene editing technology, has raised nearly $16 million from investors in what it described as an oversubscribed round of venture capital.
Read MoreA group of venture capital investors have sold $38.4 million worth of stock in G1 Therapeutics.
Read MoreAn all-star list of Triangle investors is backing Durham pharmaceutical startup Emergo Therapeutics with $12 million in venture capital.
Read More
